Navigation Links
ViroPharma to Participate in Two June Healthcare Investor Conferences
Date:6/3/2010

EXTON, Pa., June 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Jefferies 2010 Global Life Sciences Conference at 4:00 P.M. ET on Wednesday, June 9, 2010.  The conference is being held at the Grand Hyatt in New York City.

Mr. Roberts also will present at the ThinkEquity Healthcare Conference at 1:30 P.M. ET on Wednesday, June 16, 2010.  The conference is being held at the Princeton Club in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma To Host Investor Day
2. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
4. Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
5. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
6. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
7. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
11. ViroPharma Announces Discontinuation of HCV-796 Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... -- Clarivate Analytics marks the passing of one if its founding fathers, Dr. ... science in the service of scientific and scholarly research. A pioneer in ... that revolutionized the way researchers work with the literature, Garfield passed away ... ... Dr. Eugene Garfield, ...
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... 28, 2017 , ... Roxanna Cross will host a key ... Annual RISE Nashville Summit. RISE Nashville is the healthcare industry’s premier event addressing ... The discussion will include best practices for accurate identification and capture of population ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation in ... body, these individual customized retreats offer the winter-weary soul an excellent opportunity to ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... therapy, is proud to announce a new informational post on robotic hair transplantation. ... Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 INAB ... (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets ...
Breaking Medicine News(10 mins):